Logo Logo
Hilfe
Hilfe
Switch Language to English

Bartsch, Detlef K.; Gercke, Norman; Strauch, Konstantin; Wieboldt, Ronja; Matthaei, Elvira; Wagner, Vinona; Rospleszcz, Susanne; Schaefer, Agnes; Franke, Frederike S.; Mintziras, Ioannis; Bauer, Christian; Grote, Tobias; Figiel, Jens; Di Fazio, Pietro; Burchert, Andreas; Reinartz, Silke; Pogge von Strandmann, Elke; Kloeppel, Guenter und Slater, Emily P. (2018): The Combination of MiRNA-196b, LCN2, and TIMP1 is a Potential Set of Circulating Biomarkers for Screening Individuals at Risk for Familial Pancreatic Cancer. In: Journal of Clinical Medicine, Bd. 7, Nr. 10, 295 [PDF, 476kB]

[thumbnail of jcm-07-00295.pdf]
Vorschau
Download (476kB)

Abstract

Individuals at risk (IAR) of familial pancreatic cancer (FPC) are good candidates for screening. Unfortunately, neither reliable imaging modalities nor biomarkers are available to detect high-grade precursor lesions or early cancer. Circulating levels of candidate biomarkers LCN2, TIMP1, Glypican-1, RNU2-1f, and miRNA-196b were analyzed in 218 individuals with sporadic pancreatic ductal adenocarcinoma (PDAC, n = 50), FPC (n = 20), chronic pancreatitis (n = 10), IAR with relevant precursor lesions (n = 11) or non-relevant lesions (n = 5), 20 controls, and IAR with (n = 51) or without (n = 51) lesions on pancreatic imaging. In addition, corresponding duodenal juice samples were analyzed for Glypican-1 (n = 144) enrichment and KRAS mutations (n = 123). The panel miR-196b/LCN2/TIMP1 could distinguish high-grade lesions and stage I PDAC from controls with absolute specificity and sensitivity. In contrast, Glypican-1 enrichment in serum exosomes and duodenal juice was not diagnostic. KRAS mutations in duodenal juice were detected in 9 of 12 patients with PDAC and only 4 of 9 IAR with relevant precursor lesions. IAR with lesions on imaging had elevated miR-196b/LCN2/TIMP1 levels (p = 0.0007) and KRAS mutations in duodenal juice (p = 0.0004) significantly more often than IAR without imaging lesions. The combination miR-196b/LCN2/TIMP1 might be a promising biomarker set for the detection of high-grade PDAC precursor lesions in IAR of FPC families.

Dokument bearbeiten Dokument bearbeiten